← Insulin × glycemic control

TrialThe Journal of clinical endocrinology and metabolism2023

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.

Samuel Dagogo-Jack et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2023

Not counted

Probably lowered glycemic control

−30%−42% to −16%

Bigger than 3 in 10 for glycemic control

As reported

HR 0.70, 95% CI 0.58–0.84

Not counted

Probably lowered glycemic control

−36%−47% to −22%

Bigger than 3 in 10 for glycemic control

As reported

HR 0.64, 95% CI 0.53–0.78

Not counted

Probably lowered glycemic control

−38%−48% to −25%

Bigger than 4 in 10 for glycemic control

As reported

HR 0.62, 95% CI 0.52–0.75

Not counted

Probably lowered glycemic control

−49%−59% to −38%

Bigger than 5 in 10 for glycemic control

As reported

HR 0.51, 95% CI 0.41–0.62

Four numbers in the abstract

the abstract, start to end

… (ertugliflozin 5 mg: hazard ratio [HR] 0.70, 95% CI 0.58-0.84; ertugliflozin 15 mg: HR 0.64, 95% CI 0.53-0.78).

… vs placebo (ertugliflozin 5 mg: HR 0.62, 95% CI 0.52-0.75; ertugliflozin 15 mg: HR 0.51, 95% CI 0.41-0.62).

← favours treatmentfavours comparator →
could be chance
Glycemic control
HR 0.700.58–0.84
Glycemic control
HR 0.640.53–0.78
Glycemic control
HR 0.620.52–0.75
Glycemic control
HR 0.510.41–0.62
SGLT2 inhibitorsInsulinGlycemic control
1 / 3

2 papers cite it

2023
2024
2025
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 36702781